Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 801–900 of 1,000
Newsom, L. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014564181 · Cited by 13
“Similarly, limited studies exist evaluating the effect of statin therapy in patients with heart failure despite a potentially high risk for ASCVD in this patient population.(1,53,54) Based on a lack of clear evidence, the guideline panel makes no recommendation regarding the use of statin therapy in patients with chro…”
BackgroundBonsu, K. O., Owusu, I. K., Buabeng, K. O., Reidpath, D. D., & Kadirvelu, A. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004706 · Cited by 14
Association between intensity of statin therapy and mortality in persons with chronic kidney disease
Walther, C. P., Richardson, P., Virani, S. S., Winkelmayer, W. C., & Navaneethan, S. D. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy237 · Cited by 14
Muthuramu, I., Mishra, M., Aboumsallem, J. P., Postnov, A. A., Gheysens, O. S., & Geest, B. D. (2019) · Aging · doi:10.18632/aging.102218 · Cited by 13
Sibley, R. A., Katz, A., & Papadopoulos, J. (2020) · Hospital Pharmacy · doi:10.1177/0018578720928262 · Cited by 12
Low-density lipoprotein in the setting of congestive heart failure: Is lower really better?
Horwich, T. B. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0052-4 · Cited by 12
Maison, P., Désaméricq, G., Hémery, F., Elie, N., Del’Volgo, A., Dubois‐Randé, J., Hittinger, L., & Macquin‐Mavier, I. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1400-9 · Cited by 13
Filippatos, T. D., & Mikhailidis, D. P. (2008) · Angiology · doi:10.1177/0003319708319643 · Cited by 12
“The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) was the first multicenter, randomized, double-blind, placebo-controlled study that assessed the effect of a statin (rosuvastatin) administration in CHF patients.(22) The study included 5011 patients with (1) ischemic cardiomyopathy and symptomat…”
MethodPentraxin‐3 and the Right Ventricle: The Multi‐Ethnic Study of Atherosclerosis–Right Ventricle Study
Leary, P. J., Jenny, N. S., Barr, R. G., Bluemke, D. A., Harhay, M. O., Heckbert, S. R., Kronmal, R. A., Lima, J. A. C., Mikacenic, C. R., Tracy, R. P., et al. (2014) · Pulmonary Circulation · doi:10.1086/675988 · Cited by 14
Pharmacovigilance Working Party (PhVWP)
Wharf, C., London, E., O’Malley, K., & Terrace, E. (2011) · Cited by 12
Dandapat, S., & Robinson, J. G. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0621-1 · Cited by 12
Chu, C., Ke, L., Chan, H., Chan, H.-C., Cheng, K., Cheng, K.-H., Lee, H.-C., Kuo, H.-F., Chang, C.-T., Chang, K.-C., et al. (2016) · PubMed Central · doi:10.6515/acs20151228e · Cited by 12
Prognostic Value of Chronic Kidney Disease Measures in Patients With Cardiac Disease
Mok, Y., Ballew, S. H., & Matsushita, K. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0550 · Cited by 13
Lourenço, P., Pereira, J. M., Ribeiro, A., Ferreira‐Coimbra, J., Barroso, I., Guimarães, J. T., Leite-Moreira, A. F., & Bettencourt, P. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000726 · Cited by 13
Kloer, H.-U., Belardinelli, R., Ou, R., & Rosenfeldt, F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.08.017 · Cited by 14
Mega-Trials in Heart Failure: Effects of Dilution in Examination of New Therapies
Davison, B. A., Takagi, K., Senger, S., Koch, G. G., Metra, M., Kimmoun, A., Mebazaa, A., Voors, A. A., Nielsen, O. W., Chioncel, O. D., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1780 · Cited by 13
Epigenetic remodeling in heart failure with preserved ejection fraction
Ambrosini, S., Gorica, E., Mohammed, S. A., Costantino, S., Ruschitzka, F. T., & Paneni, F. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000961 · Cited by 13
Statin Therapy Decreases Myocardial Function as Evaluated Via Strain Imaging
Rubinstein, J., Aloka, F., & Abela, G. S. (2009) · Clinical Cardiology · doi:10.1002/clc.20644 · Cited by 11
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA
Barrios, V., & Escobar, C. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.119 · Cited by 13
Self-citationRelation of Statin Therapy to Risk of Heart Failure After Acute Myocardial Infarction
Aronson, D., Mutlak, D., Lessick, J., Kapeliovich, M. R., Dabbah, S., Markiewicz, W., Beyar, R., Hammerman, H., Reisner, S. A., & Agmon, Y. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.057 · Cited by 12
de Lorgeril, M., Hamazaki, T., Kostucki, W., Okuyama, H., Pavy, B., McGill, A., & Rabaeus, M. (2012) · Reviews on Recent Clinical Trials · doi:10.2174/157488712800100279 · Cited by 15
“In addition, the most recent meta-analyses omitted results from recent trials in diabetics in their primary analyzes [23, 24] and were limited by the inclusion of data from nonrandomized subgroups of diabetics [23, 24], a strategy that has been shown to be misguided in various clinical contexts [25-32].”
BackgroundResultChronic heart failure: epidemiology, investigation and management
Beggs, S. A. S., McDonagh, T. A., & Gardner, R. S. (2018) · Medicine · doi:10.1016/j.mpmed.2018.07.006 · Cited by 12
Lipophilicity and cardiovascular outcome in patients with CHF
Ford, J. S., & Tayek, J. A. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.04.025 · Cited by 12
Peikert, A., Vacca, A., Norata, G. D., Schiattarella, G. G., & Osto, E. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012674 · Cited by 22
Winter, M. J., Ono, Y., Ball, J. S., Walentinsson, A., Michaëlsson, E., Tochwin, A., Scholpp, S., Tyler, C. R., Rees, S., Hetheridge, M. J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.827686 · Cited by 11
Huang, J., Chan, Y., Tse, Y., Yu, S.-Y., Li, H., Chen, C., Zhao, C., Liu, M., Wu, M., Ren, Q. W., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.032378 · Cited by 12
Islam, M. N., Mishra, V. K., Munalisa, R., Parveen, F., Ali, S. F., Akter, K., Ahmed, T., Ho, T., & Huang, C. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00424-4 · Cited by 11
Nielsen, R. R., Pryds, K., Olesen, K. K. W., Mortensen, M. B., Gyldenkerne, C., Nielsen, J. C., Hindricks, G., Dagres, N., & Mæng, M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033938 · Cited by 11
Management of Chronic Cardiorenal Syndrome
Attanasio, P., Ronco, C., Anker, M. S., Ponikowski, P. P., & Anker, S. D. (2010) · Contributions to nephrology · doi:10.1159/000313751 · Cited by 10
CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT RECIPIENTS
McQuarrie, E. P., Fellström, B., Holdaas, H., & Jardine, A. G. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00160.x · Cited by 11
“It is likely that this alteration in proportions reflects an increase in the risk of death due to primary arrhythmia or heart failure, a pattern similar to that seen in patients with CHF or cardiomyopathy (Kjekshus et al. 2007; Lo & Hsia 2008).”
BackgroundResultToth, P. P., Thanassoulis, G., Williams, K., Furberg, C. D., & Sniderman, A. D. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.004 · Cited by 11
Broch, K., Askevold, E. T., Gjertsen, E., Ueland, T., Yndestad, A., Godang, K., Stueflotten, W., Andreassen, J., Svendsmark, R., Smith, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089732 · Cited by 12
Self-citationNoaman, S. Q., Ibrahim, J., & Grenfell, R. D. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.03.002 · Cited by 13
“CORONA [15] At least 60 years 73 +- 7.”
BackgroundResultInfluentialThe role of statins in chronic heart failure
Sadek, M. M., Haddad, T., & Haddad, H. A. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283229afb · Cited by 11
Núñez, J. E., Sanchís, J. M., Núñez, E., Fonarow, G. C., Bodí, V., Bertomeu‐González, V., Miñana, G., Palau, P., Fácila, L., Chorro, F. J., et al. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.05.033 · Cited by 11
Statin-Induced Low Cholesterol is Not Associated With Poor Outcome in Chronic Heart Failure
Silva, S., Lourenço, P., Paulo, C., Ferreira, E., Lebreiro, A., Sousa, A., Mascarenhas, J., Patacho, M., Araújo, J. P., & Bettencourt, P. (2011) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248411429967 · Cited by 11
Volpe, M., Volpe, R., Gallo, G., Presta, V., Tocci, G., Folco, E., Peracino, A. P., Tremoli, E., & Trimarco, B. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0211-6 · Cited by 13
Bauters, C., Tricot, O., Lemesle, G., Meurice, T., Hennebert, O., Farnier, M., & Lamblin, N. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.07.007 · Cited by 13
Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies
Khan, I., Peterson, E. D., Cannon, C. P., Sedita, L. E., Edelberg, J. M., & Ray, K. K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016506 · Cited by 10
Genuine versus bogus scientific controversies: the case of statins
Martini, C. M. C., & Andreoletti, M. (2021) · History & Philosophy of the Life Sciences · doi:10.1007/s40656-021-00456-w · Cited by 15
Cleland, J. G. F., Squire, I. B., & Ng, L. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.070 · Cited by 11
Self-citationLipid abnormalities and cardiovascular risk in the elderly
Milionis, H. J., Elisaf, M., & Mikhailidis, D. P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x273363 · Cited by 12
Maejima, Y., Nobori, K., Ono, Y., Adachi, S., Suzuki, J., Hirao, K., Isobe, M., Ito, H., & Coadminist, F. T. H. F. B. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-0804 · Cited by 11
Discontinuation of Statins: What Are the Risks?
Marrs, J. C., & Kostoff, M. D. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0596-z · Cited by 10
Choi, S., Yang, B. R., Kang, H., Park, K. S., & Kim, H.-S. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.312 · Cited by 11
“Two large trials, the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure (the GISSI-HF) trial, failed to confirm the beneficial effect of statins in heart failure patients [28,29].”
ResultStatins and primary prevention of cardiovascular events
Donner‐Banzhoff, N., & Sönnichsen, A. C. (2008) · BMJ · doi:10.1136/bmj.a2576 · Cited by 11
Treatment Strategies for the Prevention of Heart Failure
Grodin, J. L., & Tang, W. H. W. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0154-8 · Cited by 10
Influence of Predictive Modeling in Implementing Optimal Heart Failure Therapy
Prasad, H., Sra, J., Stapleton, D. D., & Levy, W. C. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ff2393 · Cited by 11
Role of Antithrombotic Agents in Heart Failure
Cleland, J. G. F., Mumtaz, S., & Cecchini, L. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0266-x · Cited by 10
“Aspirin remains the most widely used antithrombotic agent in patients with heart failure in sinus rhythm [40].”
BackgroundSelf-citationHaver, V. G., Verweij, N., KJEKSHUS, J. K., Fox, J. C., Wedel, H., Wikstrand, J., van Gilst, W. H., de Boer, R. A., van Veldhuisen, D. J., & van der Harst, P. (2014) · BMC Medical Genetics · doi:10.1186/s12881-014-0140-3 · Cited by 11
Self-citationRisk Markers for Atherothrombotic Disease
Ridker, P. M., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00044-5 · Cited by 16
Hammad, M. A., Abdo, M. S., Mashaly, A. M., Sulaiman, S. A. S., Alghamdi, S., Mangi, A. A., & Noor, D. A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.005 · Cited by 10
Preoperative Statin Therapy and Heart Transplantation Outcomes
Peled, Y., Klempfner, R., Kassif, Y., Kogan, A., Maor, E., Sternik, L., Lavee, J., & Ram, E. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.02.005 · Cited by 11
Epigenetic remodeling in heart failure with preserved ejection fraction
Ambrosini, S., Gorica, E., Mohammed, S. A., Costantino, S., Ruschitzka, F. T., & Paneni, F. (2022) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-229357 · Cited by 10
High‐Impact Articles Related to the Management of Heart Failure: 2008 Update
Jackevicius, C. A., Page, R. L., II, Chow, S. L., Dunn, S. P., Lee, C. R., Ng, T. M. H., Rodgers, J. E., Vardeny, O., Wiggins, B. S., & Munger, M. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.1.82 · Cited by 11
Tekin, A., Sezgin, N., Katırçıbaşı, M. T., Tekin, G., Çölkesen, Y., Sezgin, A. T., & Müderrisoğlu, H. (2008) · Coronary Artery Disease · doi:10.1097/mca.0b013e32830d27d2 · Cited by 10
Loch, D. C., Chan, V., Hoey, A. J., & Brown, L. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00440.x · Cited by 10
Statins in the Treatment of Heart Failure
van der Harst, P., & de Boer, R. A. (2010) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.956342 · Cited by 10
Savarese, G., Rosano, G. M. C., Parente, A., D’Amore, C., Reiner, M. F., Camici, G. G., Trimarco, B., & Filardi, P. P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.028 · Cited by 10
“trials not reporting CRP values or outcomes) and 22 trials [5,6,14–33]werefinally included in the analysis, encompassing 54,213 patients, e.”
BackgroundInfluentialCoenzyme Q10 and congestive heart failure; an evolving evidence base
Florkowski, C. M., Molyneux, S. L., & Young, J. M. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0015 · Cited by 10
Androgen Deficiency in Heart Failure
Güder, G., Allolio, B., Angermann, C. E., & Störk, S. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-011-0053-9 · Cited by 11
“For instance, lipid-lowering therapy with statins did not reduce mortality risk and cardiovascular end points in these patients [23, 24 ].”
BackgroundOh, J., Kang, S., Hong, N., Youn, J., Park, S., Lee, S., & Choi, D. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0670 · Cited by 11
Randomized Clinical Outcome Trials of Statins in Heart Failure
Fonarow, G. C. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.02.001 · Cited by 10
Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1586-3_17 · Cited by 10
Who does not need a statin: too late in end-stage renal disease or heart failure?
Laufs, U., Custodis, F., & Böhm, M. (2008) · Postgraduate Medical Journal · doi:10.1136/hrt.2007.125013 · Cited by 10
Self-citationPerkutaner Aortenklappenersatz – Pro: Perkutane Aortenklappenimplantation: Chance oder Risiko?
Buellesfeld, L., & Grube, E. (2009) · Herz · doi:10.1007/s00059-009-3213-x · Cited by 10
Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.071 · Cited by 10
Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?
Curtiss, F. R., & Fairman, K. A. (2010) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2010.16.6.417 · Cited by 10
Rosuvastatin and Cardiovascular Continuum
Barrios, V., & Escobar, C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.031 · Cited by 10
Self-citationFayol, A., Schiele, F., Ferrières, J., Puymirat, É., Bataille, V., Tea, V., Chamandi, C., Albert, F., Lemesle, G., Cayla, G., et al. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.123.010685 · Cited by 10
Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies
Jiang, Y., Zhou, G., Guo, Y., & Long, Y. (2025) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2024.0050 · Cited by 18
Li, W., Wu, C., Li, W., & Li, L. (2025) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2025.108224 · Cited by 11
Canepa, M., Anastasia, G., Ameri, P., Vergallo, R., O’Connor, C. M., Sinagra, G., & Porto, I. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.02.004 · Cited by 9
Marchioli, R., & Levantesi, G. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.041 · Cited by 10
“In GISSI-HF, the benefit on atherothrombotic events, namely MI and stroke, was smaller than in GISSI-Prevenzione [20], probably due to the biological milieu in HF patients not favouring the progression of coronary artery disease,with a consequent low frequency of such events [21–24].”
BackgroundOgungbe, O., Grant, J. K., Ayoola, A., Bansah, E. C., Miller, H., Plante, T. B., Sheikhattari, P., Commodore-Mensah, Y. Y., Turkson‐Ocran, R., Juraschek, S. P., et al. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01942-2 · Cited by 10
Efentakis, P., Varela, A., Lamprou, S., Papanagnou, E., Chatzistefanou, M., Christodoulou, A., Davos, C. H., Gavriatopoulou, M., Trougakos, I. P., Dimopoulos, M. A., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16391 · Cited by 11
RetractedThe use of statins in patients with heart failure: more questions than answers.
Westman, P. C., & Lipinski, M. J. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.10.47 · Cited by 9
Reed, S. D., Neilson, M. P., Gardner, M., Li, Y., Briggs, A. H., Polsky, D. E., Graham, F. L., Bowers, M., Paul, S. C., Granger, B. B., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.08.015 · Cited by 13
Statin-Associated Adverse Events
Yuet, W. C., Khine, H., & Ahmad, Z. (2015) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18865 · Cited by 9
Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation
Psarros, C. T., Economou, E. K., Koutsilieris, M., & Antoniades, C. A. (2015) · The Journal of Critical Care Medicine · doi:10.1515/jccm-2015-0007 · Cited by 9
Evaluation of the predictors of readmission in Korean patients with heart failure
Chung, J. E., Noh, E., & Gwak, H. S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12471 · Cited by 12
Cho, J., Park, I. B., Lee, K., Ahn, T. H., Park, W. B., Kim, J. H., Ahn, Y., Jeong, M. H., & Lee, D. H. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.10.009 · Cited by 9
Kosuma, P., & Jedsadayanmata, A. (2019) · Clinical Medicine Insights Cardiology · doi:10.1177/1179546819855656 · Cited by 9
Management of left ventricular diastolic heart failure: is it only blood pressure control?
Koprowski, A., Gruchała, M., & Rynkiewicz, A. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328320d530 · Cited by 10
Cornel, J. H., Lópes, R. D., James, S. K., Stevens, S. R., Neely, M. L., Liaw, D., Miller, J., Mohan, P., Amerena, J. V., Raev, D. H., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2014.12.022 · Cited by 9
Self-citationLipid Management in the Geriatric Patient
Nair, A. P., & Darrow, B. J. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.003 · Cited by 9
“medical therapy were assigned randomly to receive rosuvastatin, 10 mg/d, or placebo.(55) Patients were followed for a median duration of 32.”
MethodStatin-Induced Diabetes: Will It Change Clinical Practice?
Belalcazar, L. M., Raghavan, V. A., & Ballantyne, C. M. (2009) · Diabetes Care · doi:10.2337/dc09-1277 · Cited by 11
Role of lipids and lipoproteins in myocardial biology and in the development of heart failure
Muthuramu, I., Singh, N., Amin, R., & Geest, B. D. (2015) · Clinical Lipidology · doi:10.2217/clp.15.20 · Cited by 12
Zachrison, K. S., Levine, D. A., & Hayward, R. A. (2015) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2015-110170 · Cited by 10
The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure
Weeks, P. A., Sieg, A. C., Gass, J. A., & Rajapreyar, I. N. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9546-7 · Cited by 9
Statistical evidence and the reliability of medical research
Andreoletti, M., & Teira, D. (2016) · UNED repository · doi:10.4324/9781315720739.ch20 · Cited by 10
Kwan, A. C., Aronis, K. N., Sandfort, V., Blumenthal, R. S., & Bluemke, D. A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1348228 · Cited by 9
PHARMACOTHERAPY OF HEART FAILURE
Vittalrao, A. M., Thanusubramanian, H., Kumari, M., & Shaik, A. B. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i6.23712 · Cited by 10
Statin treatment and increased diabetes risk. Possible mechanisms
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.10.003 · Cited by 9
Rosuvastatin and Cardiovascular Disease: Did the Strongest Statin Hold the Initial Promises?
Efthimiadis, A. (2008) · Angiology · doi:10.1177/0003319708321668 · Cited by 9
Hoppe, U. C., Böhm, M., Drexler, H., Hasenfuss, G. P., Lemke, B., Osterspey, A., & Pauschinger, M. (2008) · Der Kardiologe · doi:10.1007/s12181-008-0146-1 · Cited by 11
Self-citationAlba, A. C., & Delgado, D. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.7.2.147 · Cited by 9
Qian, C., Schoemaker, R. G., van Gilst, W. H., Yu, B., & Roks, A. J. M. (2008) · Netherlands Heart Journal · doi:10.1007/bf03086169 · Cited by 11
Pasceri, V., Patti, G., & Sciascio, G. D. (2008) · PubMed · Cited by 9
Coenzyme Q10 and Statins in Heart Failure
Felker, G. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.088 · Cited by 9
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.